Mark Carbeau, Kenneth Kornman
Apr 07, 2015
Interleukin Genetics announced the appointment of Mark Carbeau as its new CEO and director. Carbeau will take over the CEO post from Kenneth Kornman, who has served as CEO and president since August 2012.
Carbeau was co-founder and CEO of Diagnostyx, a company focused on intelligent drug infusion systems. Before that, Carbeau was CEO of PolyRemedy, a company that aimed to improve wound healing outcomes by combining health IT and personalized therapeutics. Kornman will continue at Interleukin as president, chief scientific officer, and as a director.